OBJECTIVE: Periventricular white matter injury (PWMI), a precursor of cerebral palsy, traditionally is not diagnosed until 6 weeks of life by head ultrasound scanning. We sought to determine whether early neonatal glial fibrillary acidic protein (GFAP) levels could identify PWMI in low birthweight (<2500 g) infants. STUDY DESIGN: Each case with PWMI on head ultrasound scanning at 6 weeks of life from April 2009 to April 2011 was matched by gestational age and mode of delivery to 2 subsequent neonates with a normal head ultrasound scan. GFAP was measured in cord blood at birth, at neonatal intensive care unit admission, and on days 1-4 of life. RESULTS: During this 2-year period, 21 cases with PWMI with gestational age 27.4 ± 3.3 weeks were compared with 42 control infants. The incidence of cesarean delivery was 61.9% in both groups. GFAP was not significantly different in cord blood or at neonatal intensive care unit admission but was significantly elevated on day 1 (median, 5-95%; 0, 0-0.98 ng/mL cases; 0, 0-0.06 ng/mL control infants; P = .03), day 2 (0, 0-1.21 ng/mL; 0, 0-0.05 ng/mL, respectively; P = .02), day 3 (0.05, 0-0.33 ng/mL; 0, 0-0.04 ng/mL, respectively; P = .004), and day 4 (0.02, 0-1.03 ng/mL; 0, 0-0.05 ng/mL, respectively; P < .001). The odds of the development of PWMI significantly increased with increasing levels of GFAP from day 1-4 of life when adjustment was made for preeclampsia, antenatal steroid administration, and neonatal chronic lung disease. CONCLUSION: The ability to predict PWMI with a blood test for GFAP shortly after birth opens the possibility for rapid identification of infants for early intervention and provides a benchmark for the qualification of new therapies to improve neurodevelopmental outcomes.
OBJECTIVE:Periventricular white matter injury (PWMI), a precursor of cerebral palsy, traditionally is not diagnosed until 6 weeks of life by head ultrasound scanning. We sought to determine whether early neonatal glial fibrillary acidic protein (GFAP) levels could identify PWMI in low birthweight (<2500 g) infants. STUDY DESIGN: Each case with PWMI on head ultrasound scanning at 6 weeks of life from April 2009 to April 2011 was matched by gestational age and mode of delivery to 2 subsequent neonates with a normal head ultrasound scan. GFAP was measured in cord blood at birth, at neonatal intensive care unit admission, and on days 1-4 of life. RESULTS: During this 2-year period, 21 cases with PWMI with gestational age 27.4 ± 3.3 weeks were compared with 42 control infants. The incidence of cesarean delivery was 61.9% in both groups. GFAP was not significantly different in cord blood or at neonatal intensive care unit admission but was significantly elevated on day 1 (median, 5-95%; 0, 0-0.98 ng/mL cases; 0, 0-0.06 ng/mL control infants; P = .03), day 2 (0, 0-1.21 ng/mL; 0, 0-0.05 ng/mL, respectively; P = .02), day 3 (0.05, 0-0.33 ng/mL; 0, 0-0.04 ng/mL, respectively; P = .004), and day 4 (0.02, 0-1.03 ng/mL; 0, 0-0.05 ng/mL, respectively; P < .001). The odds of the development of PWMI significantly increased with increasing levels of GFAP from day 1-4 of life when adjustment was made for preeclampsia, antenatal steroid administration, and neonatal chronic lung disease. CONCLUSION: The ability to predict PWMI with a blood test for GFAP shortly after birth opens the possibility for rapid identification of infants for early intervention and provides a benchmark for the qualification of new therapies to improve neurodevelopmental outcomes.
Authors: O Baud; L Foix-L'Helias; M Kaminski; F Audibert; P H Jarreau; E Papiernik; C Huon; J Lepercq; M Dehan; T Lacaze-Masmonteil Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: Lianne J Woodward; Peter J Anderson; Nicola C Austin; Kelly Howard; Terrie E Inder Journal: N Engl J Med Date: 2006-08-17 Impact factor: 91.245
Authors: P E Vos; K J B Lamers; J C M Hendriks; M van Haaren; T Beems; C Zimmerman; W van Geel; H de Reus; J Biert; M M Verbeek Journal: Neurology Date: 2004-04-27 Impact factor: 9.910
Authors: Maria Andrikopoulou; Ahmad Almalki; Azadeh Farzin; Christina N Cordeiro; Michael V Johnston; Irina Burd Journal: Int J Dev Neurosci Date: 2014-04-24 Impact factor: 2.457
Authors: Andrew Laflam; Brijen Joshi; Kenneth Brady; Gayane Yenokyan; Charles Brown; Allen Everett; Ola Selnes; Edward McFarland; Charles W Hogue Journal: Anesth Analg Date: 2015-01 Impact factor: 5.108
Authors: Eric M Graham; Renee' H Martin; Andrew M Atz; Kasey Hamlin-Smith; Minoo N Kavarana; Scott M Bradley; Bahaaldin Alsoufi; William T Mahle; Allen D Everett Journal: J Thorac Cardiovasc Surg Date: 2019-01-23 Impact factor: 5.209
Authors: Daijiro Hori; Allen D Everett; Jennifer K Lee; Masahiro Ono; Charles H Brown; Ashish S Shah; Kaushik Mandal; Joel E Price; Laeben C Lester; Charles W Hogue Journal: Ann Thorac Surg Date: 2015-07-07 Impact factor: 4.330
Authors: Sandra Brooks; Barbara D Friedes; Frances Northington; Ernest Graham; Aylin Tekes; Vera J Burton; Gwendolyn Gerner; Jie Zhu; Raul Chavez-Valdez; Dhananjay Vaidya; Allen D Everett Journal: Pediatr Res Date: 2021-12-18 Impact factor: 3.953
Authors: T Rappold; A Laflam; D Hori; C Brown; J Brandt; C D Mintz; F Sieber; A Gottschalk; G Yenokyan; A Everett; C W Hogue Journal: Br J Anaesth Date: 2016-01 Impact factor: 9.166
Authors: Jeremiah R Brown; Meagan E Stabler; Devin M Parker; Luca Vricella; Sara Pasquali; JoAnna K Leyenaar; Andrew R Bohm; Todd MacKenzie; Chirag Parikh; Marshall L Jacobs; Jeffrey P Jacobs; Allen D Everett Journal: Cardiol Young Date: 2019-07-10 Impact factor: 1.093
Authors: William Schleif; Frances Hamblin; Allen D Everett; Ernest M Graham; Jennifer Cross; Christy Fernald; Robert Follett; Bryan Lopes; Denise Martinez; Hector Monforte; Jennifer Ross-Wilkinson; Austin Sellers; Sandra Brooks Journal: Biopreserv Biobank Date: 2021-01-21 Impact factor: 2.300